Birchview Capital
Birchview Capital reported 72 stocks worth $214M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are KLAC (25.2%), BMY (8.0%) and LRCX (7.1%). Compared with Q1 2026, the fund opened new positions in ABVX, VIR and BIOA, added to KLAC, SLDB and NKTR, trimmed BMY, LRCX and NTLA and sold out of NVCR, RARE and VSTM.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  KLAC Kla Corp | $53.8M | 25.2% | 178K | +159K (+798%) | 5 of 8 | |
| 2 |  BMY Bristol Myers Squibb Co | $17.1M | 8.0% | 297K | −9,025 (−3%) | 8 of 8 | |
| 3 |  LRCX Lam Research Corp | $15.2M | 7.1% | 35K | −1,000 (−3%) | 3 of 8 | |
| 4 |  NTLA Intellia Therapeutics Inc | $6.8M | 3.2% | 386K | −60K (−13%) | 5 of 8 | |
| 5 |  SLDB Solid Biosciences Inc | $6.7M | 3.1% | 666K | +40K (+6%) | 6 of 8 | |
| 6 |  BDSX Biodesix Inc | $6.5M | 3.0% | 287K | No change | 8 of 8 | |
| 7 |  STOK Stoke Therapeutics Inc | $5.8M | 2.7% | 178K | −32K (−15%) | 8 of 8 | |
| 8 |  OVV Ovintiv Inc | $5.7M | 2.6% | 108K | No change | 8 of 8 | |
| 9 |  NKTR Nektar Therapeutics | $5.7M | 2.6% | 81K | +50K (+161%) | 4 of 8 | |
| 10 |  CORT Corcept Therapeutics Inc | $5M | 2.3% | 57K | +10K (+21%) | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 NVCR Novocure Ltd | $2.2M | 202K |
ENGENE HOLDINGS INC | $1.7M | 250K |
 RARE Ultragenyx Pharmaceutical in | $1.3M | 62K |
KALVISTA PHARMACEUTICALS INC | $1.1M | 57K |
 VSTM Verastem Inc | $795K | 150K |
🔒 Free account: see all 15.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Birchview Capital 13F FAQ
What does Birchview Capital own?
Birchview Capital reported 72 stocks worth $214M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are KLAC (25.2%), BMY (8.0%) and LRCX (7.1%). The table above lists every position in the filing (the top 10 without an account).
What did Birchview Capital buy and sell in Q2 2026?
Compared with Q1 2026: 14 new positions, 16 added to, 20 trimmed and 15 sold out. New positions include ABVX, VIR and BIOA. It sold all of NVCR, RARE and VSTM.
When will Birchview Capital file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Birchview Capital's portfolio worth?
The Q2 2026 filing reports $214M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.